Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million ...

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations with its "follow and win the molecule" and global dual sourcing strategies.

WuXi Biologics hat erneut den CDMO Leadership Award in der Kategorie "Biologics - Global" erhalten und setzt damit seine Erfolgsserie fort. Die Auszeichnung, die das Unternehmen zum achten Mal in ...

Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...

SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has ...

We have raised our fair value estimate for narrow-moat-rated WuXi Biologics to HKD 26.60 per share from HKD 24.60 following better-than-expected 2024 results and strong guidance for 2025.

WuXi AppTec (Shanghai, China) has sold off two US/UK businesses in February and March, it revealed in its annual results on 18 March 2025. The Chinese contract research, development, and ...

Talents People are WuXi Biologics' greatest assets. As of December 31, 2024, the Group's total employee count reached 12,575, including 4,383 scientists, with a key talent retention rate of 95.8%. The ...